Innovative formula – a combination of three ingredients:
Results from Safr’insideTM manufacturer research:
scroll down for details
Couldn't load pickup availability
Save up to 20% on every jar
Free shipping to Poland for orders over 150 PLN
Edit or cancel anytime
Order once, and we deliver regularly
Shipping to Poland 15 PLN
The manufacturer’s ex vivo study of Safr’inside™ showed that it supports the balance of brain neurotransmitters responsible for mood and emotional state. The result? Increased serotonin levels(1).
The manufacturer’s ex vivo study of Safr’inside™ showed that it reduces levels of free radicals (ROS) caused by oxidative stress – protecting neurons from its toxic effects(1).
The manufacturer’s study of Safr’inside™ showed that it helps maintain nervous system balance and heart rate variability in stressful situations(2). Works in under 30 minutes.
The manufacturer’s study of Safr’inside™ showed that it helps reduce anxiety by restoring a healthy microbiota – particularly by increasing levels of Akkermansia(1). A prebiotic effect.
The manufacturer’s study showed that Safr’Inside™ and its active compound, safranal, modulate the body’s biological response to stress(3). Similar effects were observed in studies conducted by the manufacturer of L-theanine(8-10). A fast physiological response – in under 30 minutes.
The manufacturer’s ex vivo study showed that Safr’Inside™ reduces inflammation in intestinal and joint cells – demonstrating a systemic anti-inflammatory effect(3).
Niacin supports the normal functioning of the nervous system(5) and psychological function(7). It also helps reduce feelings of fatigue and tiredness(4) and supports normal energy metabolism(6).
The manufacturer’s study of Safr’inside™ showed that it improves sleep quality, shortens time to fall asleep (by 35.4%), and supports overnight recovery(11,12). In studies, saffron extract delivered effects comparable to melatonin – without the side effects typically associated with supplementation with the sleep hormone(13). Works naturally, without dependence or mental fog – supports calm in the evening while maintaining alertness during the day.
The manufacturer’s study of saffron extract showed a significant reduction in PMS symptoms – including irritability, tension, and mood swings(15). Improvements were observed after just two cycles.
In a 12-week manufacturer-led study, saffron extract significantly reduced symptoms of anxiety and low mood in perimenopausal women – by over 30% compared to placebo(16).
In manufacturer-led studies comparing Safr’Inside™ with standard pharmacological approaches, an improvement in depressive symptoms on the POMS scale was observed after 8 weeks of Safr’Inside™ use. Effects were noticeable as early as 6 weeks.
The manufacturer’s study of Safr’Inside™: 50 healthy adults | 30 mg / day | 30 days of supplementation(14).
report greater optimism
noticed an improvement in emotional balance
consumers experienced improved sleep quality
Recommended intake: 3 gummies per day, taken at once, at any time of day.
Ingredients
Chemical form
Quantity (in 3 gummies)
NRV (%)
L-theanine
Safr’Inside™ saffron extract
Vitamin B3 (niacin)
NRV (%) – Nutrient Reference Value
Nutritional value (100 g / 3 gummies): energy 261 kcal / 19.58 kcal, fat (of which saturates) <0.5 g (<0.5 g) / <0.5 g (<0.5 g), carbohydrates (of which sugars) 43 g (39 g) / 3.23 g (2.93 g), fiber 33 g / 2.48 g, protein 0.74 g / 0.06 g, salt 1.1 g / 0.08 g.
Other ingredients: apple juice concentrate, tapioca fiber, gelling agent (pectin), acidity regulator (citric acid), natural color (carrot, cherry), natural flavor (including blackcurrant), glazing agents (organic sunflower oil, organic carnauba wax).
Do not exceed the recommended daily dose. Food supplements should not be used as a substitute for a varied diet. A balanced diet and a healthy lifestyle are important for the proper functioning of the body. Store the product sealed, below 21°C, in a dry, dark place and out of reach of young children.
Read the article
Ashwagandha has seen a rapid rise in popularity – in recent years, it has appeared in thousands of dietary supplements across Europe and is promoted as a natural solution for stress, fatigue, insomnia, and low mood. However, this popularity is not supported by sufficient scientific evidence confirming either its effectiveness or its safety. In 2020, according to an assessment by the Danish Technical University (DTU), ashwagandha was classified as potentially unsafe because it may disrupt hormonal balance and reproductive function in both men and women. It may also negatively affect metabolism, the immune system, and the central nervous system. Denmark recommended removing ashwagandha from the market. In response, a report was published in 2024 by an expert committee appointed by India’s Ministry of AYUSH, intended to defend the safety of ashwagandha. However, this document does not meet clinical evaluation standards – it is based on a review of existing studies without assessing their quality or applying rigorous methodology. India is one of the largest exporters of ashwagandha to Europe, and the ingredient holds significant economic and symbolic importance there. Serious warnings have also come from Germany. As early as 2013, the Federal Institute for Risk Assessment (BfR) pointed to a lack of toxicological data and recommended considering restrictions on the use of ashwagandha in food products. In an opinion reaffirmed in 2024, BfR warned of a risk of liver damage and potential effects on the hormonal system. Particular concern was raised for children, pregnant women, and individuals with liver disease. At the same time, BfR emphasized the lack of clear evidence supporting the claimed health benefits. Concerns about the safety of ashwagandha have also been raised by public health authorities in other European countries, including Iceland, France, and the Nordic countries, where restrictions or further risk assessments have been suggested. At present, most available studies on ashwagandha do not meet the standards applied to ingredients intended to act on the nervous or hormonal systems. Randomized clinical trials in humans are limited, often conducted on small groups, with inconsistent results and weak methodological quality. Ashwagandha may also interact with sedative, anxiolytic, or anticonvulsant medications, intensify side effects, and affect sex hormone levels – making it contraindicated, among others, in thyroid disorders or hormone-dependent cancers. Until studies meeting modern clinical standards are available, ashwagandha remains an ingredient with an unverified safety profile – with many unknowns and potentially serious health consequences.
Ashwagandha has seen a rapid rise in popularity – in recent years, it has appeared in thousands of dietary supplements across Europe and is promoted as a natural solution for stress, fatigue, insomnia, and low mood. However, this popularity is not supported by sufficient scientific evidence confirming either its effectiveness or its safety.
In 2020, according to an assessment by the Danish Technical University (DTU), ashwagandha was classified as potentially unsafe because it may disrupt hormonal balance and reproductive function in both men and women. It may also negatively affect metabolism, the immune system, and the central nervous system. Denmark recommended removing ashwagandha from the market. In response, a report was published in 2024 by an expert committee appointed by India’s Ministry of AYUSH, intended to defend the safety of ashwagandha. However, this document does not meet clinical evaluation standards – it is based on a review of existing studies without assessing their quality or applying rigorous methodology. India is one of the largest exporters of ashwagandha to Europe, and the ingredient holds significant economic and symbolic importance there.
Serious warnings have also come from Germany. As early as 2013, the Federal Institute for Risk Assessment (BfR) pointed to a lack of toxicological data and recommended considering restrictions on the use of ashwagandha in food products. In an opinion reaffirmed in 2024, BfR warned of a risk of liver damage and potential effects on the hormonal system. Particular concern was raised for children, pregnant women, and individuals with liver disease. At the same time, BfR emphasized the lack of clear evidence supporting the claimed health benefits.
Concerns about the safety of ashwagandha have also been raised by public health authorities in other European countries, including Iceland, France, and the Nordic countries, where restrictions or further risk assessments have been suggested.
At present, most available studies on ashwagandha do not meet the standards applied to ingredients intended to act on the nervous or hormonal systems. Randomized clinical trials in humans are limited, often conducted on small groups, with inconsistent results and weak methodological quality.
Ashwagandha may also interact with sedative, anxiolytic, or anticonvulsant medications, intensify side effects, and affect sex hormone levels – making it contraindicated, among others, in thyroid disorders or hormone-dependent cancers. Until studies meeting modern clinical standards are available, ashwagandha remains an ingredient with an unverified safety profile – with many unknowns and potentially serious health consequences.
Monchaux De Oliveira, C., Pourtau, L., Vancassel, S., Pouchieu, C., Capuron, L., Gaudout, D., & Castanon, N. (2021). Saffron Extract-Induced Improvement of Depressive-Like Behavior in Mice Is Associated with Modulation of Monoaminergic Neurotransmission. Nutrients, 13(3), 904. https://doi.org/10.3390/nu13030904
Jackson PA, Forster J, Khan J, Pouchieu C, Dubreuil S, Gaudout D, Moras B, Pourtau L, Joffre F, Vaysse C, Bertrand K, Abrous H, Vauzour D, Brossaud J, Corcuff JB, Capuron L and Kennedy DO (2021) Effects of Saffron Extract Supplementation on Mood, Well-Being, and Response to a Psychosocial Stressor in Healthy Adults: A Randomized, Double-Blind, Parallel Group, Clinical Trial. Front. Nutr. 7:606124. doi: 10.3389/fnut.2020.606124
https://activinside.com/ingredients/safrinside/
EFSA. Niacin contributes to the reduction of tiredness and fatigue. POL-HC-6428
EFSA. Niacin contributes to normal functioning of the nervous system. POL-HC-6425
EFSA. Niacin contributes to normal energy-yielding metabolism. POL-HC-6424
EFSA. Niacin contributes to normal psychological function. POL-HC-6423
Evans, M., McDonald, A.C., Xiong, L. et al. A Randomized, Triple-Blind, Placebo-Controlled, Crossover Study to Investigate the Efficacy of a Single Dose of AlphaWave® l-Theanine on Stress in a Healthy Adult Population. Neurol Ther 10, 1061–1078 (2021). https://doi.org/10.1007/s40120-021-00284-x
Everett, J. M., Gunathilake, D., Dufficy, L., Roach, P. D., THOMAS, J., UPTON, D., & NAUMOVSKI, N. (2015).Theanine consumption, stress and anxiety in human clinical trials: a systematic review. 41-42. Abstract from 39th Annual Scientific Meeting of the Nutrition Society of Australia 2015, Wellington, New Zealand. https://doi.org/10.1016/j.jnim.2015.12.308
White, D. J., De Klerk, S., Woods, W., Gondalia, S., Noonan, C., & Scholey, A. B. (2016). Anti-Stress, Behavioural and Magnetoencephalography Effects of an l-Theanine-Based Nutrient Drink: A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial. Nutrients, 8(1), 53. https://doi.org/10.3390/nu8010053
Pouchieu C, Pourtau L, Brossaud J, Gaudout D, Corcuff JB, Capuron L, Castanon N, Philip P. Acute Effect of a Saffron Extract (Safr'InsideTM) and Its Main Volatile Compound on the Stress Response in Healthy Young Men: A Randomized, Double Blind, Placebo-Controlled, Crossover Study. Nutrients. 2023 Jun 27;15(13):2921. doi: 10.3390/nu15132921. PMID: 37447245; PMCID: PMC10346743.
https://nutraceuticalbusinessreview.com/activinside-safrinside-saffron-extract-sleep-study
Lopresti AL, Smith SJ, Drummond PD. An investigation into an evening intake of a saffron extract (affron®) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomised, double-blind, placebo-controlled, multi-dose study. Sleep Med. 2021 Oct;86:7-18. doi: 10.1016/j.sleep.2021.08.001. Epub 2021 Aug 11. PMID: 34438361.
Test konsumencki na 50 zdrowych osobach dorosłych, 30 mg Safr’inside™ dziennie przez 30 dni.
Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, Akhondzadeh S. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG. 2008 Mar;115(4):515-9. doi: 10.1111/j.1471-0528.2007.01652.x. PMID: 18271889.
Lopresti AL, Smith SJ. The Effects of a Saffron Extract (affron®) on Menopausal Symptoms in Women during Perimenopause: A Randomised, Double-Blind, Placebo-Controlled Study. J Menopausal Med. 2021 Aug;27(2):66-78. doi: 10.6118/jmm.21002. PMID: 34463070; PMCID: PMC8408316.
Shahmansouri N, Farokhnia M, Abbasi SH, Kassaian SE, Noorbala Tafti AA, Gougol A, Yekehtaz H, Forghani S, Mahmoodian M, Saroukhani S, Arjmandi-Beglar A, Akhondzadeh S. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord. 2014 Feb;155:216-22. doi: 10.1016/j.jad.2013.11.003. Epub 2013 Nov 16. PMID: 24289892.
Khalil, S.A. (2022). Saffron as a Treatment for Mild to Moderate Depression: A Revision of Current Literature Journal of European Psychology Students, 13(1), 1–6. https://doi.org/10.5334/jeps.529
Twoja opinia może zostać wykorzystana w naszej reklamie. Przeczytaj więcej w naszym Regulaminie. Także w opiniach dbamy o transparentność. Weryfikujemy czy pochodzą od regularnych klientów (nie osób z nami współpracujących) oraz czy są zgodne z przepisami prawa mającymi na celu ochronę konsumentów.
